Lördag 21 November | 00:14:53 Europe / Stockholm
Est. tid*
2027-10-21 07:00 Kvartalsrapport 2027-Q3
2027-07-15 07:00 Kvartalsrapport 2027-Q2
2027-06-14 N/A Årsstämma
2027-04-27 07:00 Kvartalsrapport 2027-Q1
2027-02-04 07:00 Bokslutskommuniké 2026
2026-11-06 - Extra Bolagsstämma 2026
2026-10-22 - Kvartalsrapport 2026-Q3
2026-07-16 - Kvartalsrapport 2026-Q2
2026-05-08 - X-dag ordinarie utdelning ORX 0.00 SEK
2026-05-07 - Årsstämma
2026-04-28 - Kvartalsrapport 2026-Q1
2026-02-05 - Bokslutskommuniké 2025
2025-10-23 - Kvartalsrapport 2025-Q3
2025-07-16 - Kvartalsrapport 2025-Q2
2025-05-09 - X-dag ordinarie utdelning ORX 0.00 SEK
2025-05-08 - Årsstämma
2025-05-06 - Kvartalsrapport 2025-Q1
2025-02-06 - Bokslutskommuniké 2024
2024-12-18 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-17 - Kvartalsrapport 2024-Q2
2024-05-08 - Kvartalsrapport 2024-Q1
2024-04-29 - X-dag ordinarie utdelning ORX 0.00 SEK
2024-04-26 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-10-26 - Extra Bolagsstämma 2023
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - Kvartalsrapport 2023-Q1
2023-04-19 - X-dag ordinarie utdelning ORX 0.00 SEK
2023-04-18 - Årsstämma
2023-01-26 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-04-28 - Kvartalsrapport 2022-Q1
2022-04-22 - X-dag ordinarie utdelning ORX 0.00 SEK
2022-04-21 - Årsstämma
2022-01-27 - Bokslutskommuniké 2021
2021-11-03 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-04-29 - Kvartalsrapport 2021-Q1
2021-04-14 - X-dag ordinarie utdelning ORX 0.00 SEK
2021-04-13 - Årsstämma
2021-01-28 - Bokslutskommuniké 2020
2020-11-04 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-19 - Extra Bolagsstämma 2020
2020-04-28 - Kvartalsrapport 2020-Q1
2020-04-17 - X-dag ordinarie utdelning ORX 0.00 SEK
2020-04-16 - Årsstämma
2020-01-30 - Bokslutskommuniké 2019
2019-10-24 - Kvartalsrapport 2019-Q3
2019-07-11 - Kvartalsrapport 2019-Q2
2019-05-02 - Kvartalsrapport 2019-Q1
2019-04-14 - X-dag ordinarie utdelning ORX 0.00 SEK
2019-04-11 - Årsstämma
2019-01-30 - Bokslutskommuniké 2018
2018-10-25 - Kvartalsrapport 2018-Q3
2018-07-11 - Kvartalsrapport 2018-Q2
2018-04-26 - Kvartalsrapport 2018-Q1
2018-04-13 - X-dag ordinarie utdelning ORX 0.00 SEK
2018-04-12 - Årsstämma
2018-01-25 - Bokslutskommuniké 2017
2017-10-19 - Kvartalsrapport 2017-Q3
2017-07-11 - Kvartalsrapport 2017-Q2
2017-04-20 - Kvartalsrapport 2017-Q1
2017-04-07 - X-dag ordinarie utdelning ORX 0.00 SEK
2017-04-06 - Årsstämma
2017-01-26 - Bokslutskommuniké 2016
2016-10-20 - Kvartalsrapport 2016-Q3
2016-07-12 - Kvartalsrapport 2016-Q2
2016-04-21 - Kvartalsrapport 2016-Q1
2016-04-18 - X-dag ordinarie utdelning ORX 0.00 SEK
2016-04-15 - Årsstämma
2016-01-28 - Bokslutskommuniké 2015
2015-10-22 - Kvartalsrapport 2015-Q3
2015-07-10 - Kvartalsrapport 2015-Q2
2015-04-23 - Kvartalsrapport 2015-Q1
2015-04-16 - X-dag ordinarie utdelning ORX 0.00 SEK
2015-04-15 - Årsstämma
2015-01-29 - Bokslutskommuniké 2014
2014-10-22 - Analytiker möte 2014
2014-10-22 - Kvartalsrapport 2014-Q3
2014-07-11 - Kvartalsrapport 2014-Q2
2014-04-25 - Kvartalsrapport 2014-Q1
2014-04-16 - X-dag ordinarie utdelning ORX 0.00 SEK
2014-04-15 - Årsstämma
2014-01-30 - Bokslutskommuniké 2013
2013-10-23 - Kvartalsrapport 2013-Q3
2013-08-06 - Extra Bolagsstämma 2013
2013-07-12 - Kvartalsrapport 2013-Q2
2013-04-26 - Kvartalsrapport 2013-Q1
2013-04-12 - X-dag ordinarie utdelning ORX 0.00 SEK
2013-04-11 - Årsstämma
2013-03-13 - 15-7 2013
2013-01-31 - Bokslutskommuniké 2012
2012-10-25 - Kvartalsrapport 2012-Q3
2012-09-21 - 15-7 2012
2012-07-13 - Extra Bolagsstämma 2012
2012-07-12 - Kvartalsrapport 2012-Q2
2012-05-03 - Kapitalmarknadsdag 2012
2012-04-27 - Kvartalsrapport 2012-Q1
2012-04-12 - X-dag ordinarie utdelning ORX 0.00 SEK
2012-04-11 - Årsstämma
2012-01-31 - Bokslutskommuniké 2011
2011-11-09 - Kvartalsrapport 2011-Q3
2011-08-10 - Kvartalsrapport 2011-Q2
2011-05-04 - Kvartalsrapport 2011-Q1
2011-04-08 - X-dag ordinarie utdelning ORX 0.00 SEK
2011-04-07 - Årsstämma
2011-02-16 - Extra Bolagsstämma 2011
2011-02-16 - Bokslutskommuniké 2010
2010-11-10 - Kvartalsrapport 2010-Q3
2010-08-20 - Kvartalsrapport 2010-Q2
2010-05-05 - Kvartalsrapport 2010-Q1
2010-04-22 - X-dag ordinarie utdelning ORX 0.00 SEK
2010-04-21 - Årsstämma
2010-02-17 - Bokslutskommuniké 2009
2009-11-10 - Kvartalsrapport 2009-Q3
2009-08-21 - Kvartalsrapport 2009-Q2
2009-05-06 - Kvartalsrapport 2009-Q1
2009-04-24 - X-dag ordinarie utdelning ORX 0.00 SEK
2009-04-23 - Årsstämma
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Orexo är ett svenskt läkemedelsbolag som utvecklar läkemedel baserat på egenutvecklade formuleringsteknologier och med fokus på att möta stora medicinska behov. På den amerikanska marknaden kommersialiserar Orexo behandlingar för patienter som lider av opioidberoende. Produkter som riktar sig till andra terapi­områden utvecklas och kommersialiseras världen över via partners.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

New OX640 Data Presented at ACAAI Demonstrate Rapid Achievement of Clinically Meaningful Epinephrine Levels and Enhanced Stability

2026-11-13 08:00:00

November 13, 2026

  • OX640 is a nasal rescue medication with powder-based epinephrine in clinical development for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technology.
  • OX640 rapidly reached clinically meaningful epinephrine levels, with the fastest attainment observed under allergic rhinitis conditions versus normal conditions and intramuscular epinephrine.
  • OX640 demonstrated enhanced stability, retaining more than 98% of its R-epinephrine potency after one year under accelerated aging conditions, compared with 55% for an epinephrine autoinjector and 66% for a liquid epinephrine nasal spray.

UPPSALA, Sweden – November 13, 2026 – Orexo AB (publ.) (STO: ORX) (OTCQX:ORXOY) today announced that its US subsidiary, Orexo US, Inc., presented two oral abstracts with additional data on OX640, a novel nasal epinephrine powder in clinical development, at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place in Phoenix, Arizona, November 12-16, 2026.

Dr. Anne K. Ellis, Professor and Chair of the Division of Allergy & Immunology at Queen’s University (Kingston, Ontario, Canada) and advisor to Orexo, presented an analysis of the OX640-002 study, which evaluated the time to reach the epinephrine levels of 100 and 200pg/ml, as well as time spent above these thresholds. Among other findings, OX640 reached threshold epinephrine levels fastest under allergic rhinitis conditions compared to normal conditions and compared to an epinephrine intramuscular injection.

Dr. Edward Kim, Chief Medical Officer of Orexo, also presented a poster demonstrating detailed stability for OX640, as compared to a commercially available epinephrine autoinjector and liquid epinephrine nasal spray. After one year under accelerated aging conditions, OX640 maintained more than 98% of its R-epinephrine potency, as compared to 55% with an epinephrine autoinjector and 66% of a liquid epinephrine nasal spray.

The abstracts will be available online at annualmeeting.acaai.org.

Nikolaj Sørensen, President and CEO of Orexo AB, said: “These new data add to the growing body of evidence supporting OX640 as a differentiated, needle-free epinephrine rescue treatment. The combination of rapid epinephrine absorption and enhanced product stability addresses important attributes for an emergency treatment that needs to be readily available and reliable when patients need it most.”

For further information contact:
Nikolaj Sørensen, President and CEO
ir@orexo.com

About OX640
OX640 is a powder-based intranasal formulation of epinephrine in clinical development for the emergency treatment of anaphylaxis. The product is based on Orexo’s proprietary AmorphOX® technology, which enables the formulation of medicines with improved stability and rapid absorption through the nasal mucosa. OX640 is being developed as a needle-free alternative to today’s epinephrine autoinjectors.

About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of Orexo’s innovation is AmorphOX®, a proprietary drug delivery technology designed to improve bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing, and distribution. With more than 30 years of experience and multiple medicines approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.

For more information, please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.